2016 American Transplant Congress
Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
Mononuclear phagocytes and neutrophils play a key role in early responses against the transplanted kidney allograft. It is expected that during the reperfusion of kidney…2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…2016 American Transplant Congress
Antithymocyte (ATG) Dose Density in Renal Transplant Recipients (RTR) with Early Graft Dysfunction (EGD).
Houston Methodist Hospital, Houston, TX.
The cumulative amount of ATG for induction may be given as consecutive (cDD) or intermittent day dosages (iDD). iDD allows for leukocyte or platelet recovery…2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…2016 American Transplant Congress
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.
African Americans (AA) are at a higher risk of acute rejection and graft loss compared to non-AA kidney transplant (KT) recipients. Guidelines specify induction choices…2016 American Transplant Congress
Anti-Thymocyte Globulin Induction Does Not Increase the Risk of Thrombotic Events in Kidney Transplantation: A Matched Case-Control Study.
Background: Anti-thymocyte globulin (ATG) is the most commonly used induction agent in kidney transplantation (KTx). To date, case reports and in vitro analyses have suggested…2016 American Transplant Congress
A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen.
Hospital Geral de Fortaleza, Fortaleza, Brazil.
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…2016 American Transplant Congress
Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.
University of Wisconsin, Madison.
Background: The average annual incidence of de novo donor specific antibody (DSA) has been reported as 3-4% after the first year post-transplant. Recent data suggests…2016 American Transplant Congress
Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.
Johns Hopkins University, Baltimore, MD.
Older adults are increasingly gaining access to kidney transplantation (KT) yet the use of induction agents in this population is unclear. The goal of this…2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
American Transplant Congress abstracts